A Leadership Conversation with Dr. Marty Tenenbaum and Dr. Josh LaBaer

AZBio-DorothyFoundation

March 19th, 2015 11:00 AM – 1:00 PM at Phoenix Country Club

Join AZBio and Members of Arizona’s Healthcare and Life Science Community for

Big Questions – Big Data – Big Science:

A Leadership Conversation with Dr. Marty Tenenbaum,

founder of Cancer Commons and

Dr. Josh LaBaer  of the Biodesign Institute  at ASU

It’s been said time and again that when it comes to science and research, Arizona’s pioneering spirit and youthful energy, makes it a perfect place for collaboration.

With the advance of big data, open science, crowdsourcing and the like, do we have the right people, ideas, tools, resources and motivation to accelerate cures and

bring solutions to people? What’s stopping us now?

Two ‘big idea guys’ will join us on March 19th to share their experiences, their successes – and yes, their failures.

When:  Thursday, March 19, 2015

11:00 AM –  Registrations and Networking

11:30 AM – 1:00  PM – Program and Lunch

Where:  Phoenix Country Club

Tickets:  $75 for Members*, $100 for Non Members, $750 for a table of  10    REGISTER

Elected Leaders and the Media receive complimentary registration to this educational event.

* Member pricing is extended to  Members of AZBio, the Arizona Technology Council, and the Arizona Hospital and Healthcare Association.

Every year 1.6 million Americans are diagnosed with cancer and nearly half of those cases are considered incurable. But many of those “incurable” cases may be beatable by exploiting biological features unique to each individual’s cancer. Join us as we explore the  convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment. In this new paradigm, cancer is managed as a chronic disease using an evolving cocktail of targeted- and immunotherapies individualized for each patient, much like HIV. Every treatment event is considered as a probe that  simultaneously treats the patient and provides an opportunity to validate and refine the models on which the treatment decisions are based.